Skip to Main Content

search input Search input auto suggest

Search

Menu

Innovations Journals Home
About The Journal
Browse Journal
- Ahead of Print
- All Issues
Submit an Article
For Reviewers
- Become A Reviewer
- Tips for Reviewers
Search
Contact Us
subscribe
industry news

Skip Nav Destination

Issues

Select Year

Select Issue

Volume 3, Issue 4

November 2020

ISSN 2666-2345

eISSN 2590-017X

In this Issue

ORIGINAL RESEARCH
REVIEWS
Brief Communication
ACKNOWLEDGMENTS

ORIGINAL RESEARCH

Characterization of Cutaneous Adverse Events Associated With PI3K Inhibitors in 11 Patients

Padmavathi V. Karri; Benjamin D. Freemyer; Omar Pacha; Anisha B. Patel

REVIEWS

Cancer Epigenomics and Beyond: Advancing the Precision Oncology Paradigm

Daniel Y. Lee

The Promise of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Gliomas

Nazanin Majd; Timothy A. Yap; W. K. Alfred Yung; John de Groot

Wilms' Tumor 1 (WT1): The Vaccine for Cancer

Kyaw Zaw Hein; Shuyang Yao; Siqing Fu

Brief Communication

Role of Infliximab in Immune Checkpoint Inhibitor-Induced Pneumonitis

Kathryn A. Lai; Ajay Sheshadri; Andres M. Adrianza; Mikel Etchegaray; Diwakar D. Balachandran; Lara Bashoura; Vickie R. Shannon; Saadia A. Faiz

ACKNOWLEDGMENTS

Guest Editor and Reviewer Acknowledgments: 2020

Cover Image

Cover Image

Get Email Alerts

Publish Ahead of Print Alert

Latest Issue Alert

Latest
Most Read

Hypereosinophilia: An Unusual Bystander in Cancer

Cristhiam M. Rojas-Hernandez

COVID-19 Pandemic and Cancer Clinical Trial Pandemonium: Finding the Silver Lining

Aakash Desai, Vivek Subbiah

The Impact of COVID-19 on Cancer Clinical Trials Conducted by NCI-Designated Comprehensive Cancer Centers

Diviya Gupta, Shumei Kato, Razelle Kurzrock

Guest Editor and Reviewer Acknowledgments: 2020

Wilms' Tumor 1 (WT1): The Vaccine for Cancer

Kyaw Zaw Hein, Shuyang Yao, Siqing Fu

eISSN 2590-017X
ISSN 2666-2345

Privacy Policy
Get Adobe Acrobat Reader
Support

This Feature Is Available To Subscribers Only

Sign In or Create an Account

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.

Accept